
Sign up to save your podcasts
Or


Sometimes, there’s an interview that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer look at Alzheimer’s disease with a conversation about current drugs, clinical trials, and the pipeline.
Our guest is Sharon L. Rogers, CEO of the biotech AmyriAD Therapeutics.
Sponsor
Interested in sponsoring one or more episodes of the podcast? Learn more here!
Leave a review on Apple podcasts
Reviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!
Connect with us
By Labiotech3.3
33 ratings
Sometimes, there’s an interview that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer look at Alzheimer’s disease with a conversation about current drugs, clinical trials, and the pipeline.
Our guest is Sharon L. Rogers, CEO of the biotech AmyriAD Therapeutics.
Sponsor
Interested in sponsoring one or more episodes of the podcast? Learn more here!
Leave a review on Apple podcasts
Reviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!
Connect with us

1,712 Listeners

389 Listeners

1,866 Listeners

1,081 Listeners

162 Listeners

124 Listeners

324 Listeners

60 Listeners

86 Listeners

34 Listeners

431 Listeners

146 Listeners

19 Listeners

558 Listeners

48 Listeners